Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Breast Cancer Research Program (BCRP) Funding Opportunity for Fiscal Year 2022 (FY22)

How to Apply: 

The FY22 Defense Appropriations Act provides funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members, Veterans, and the general public.  The managing agent for the anticipated funding opportunity is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

 

The FY22 BCRP funding opportunity announcement for the following award mechanism is posted on the Grants.gov website. 

 

Applications submitted to the FY22 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

 

Funding Opportunities - FY22 Breast Cancer Research Program, Congressionally Directed Medical Research Programs (CDMRP), US DoD (health.mil)

 

Clinical Research Extension Award - Letter of Intent due November 29, 2022

Investigators at all academic levels (or equivalent)

• Supports research that extends the data collection, follow-up, and analysis of breast cancer clinical research studies.

• The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.

• Although not all-inclusive, research proposed under this mechanism may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. • PIs are required to include two or more breast cancer advocates on their research team.

• Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to partner on a single application.

o Each PI is expected to bring a distinct contribution to the application.

o The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. • Submission of a Letter of Intent is required prior to full application submission.

• Clinical trials are not allowed.

 

 

 

The maximum allowable funding for the entire period of performance is $5M for direct costs (plus indirect costs).

• Maximum period of performance is 4 years Partnering PI Option:

• The maximum allowable funding for the entire period of performance is $6M for direct costs (plus indirect costs).

• Maximum period of performance is 4 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcement available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

 

Point of Contact:

CDMRP Helpdesk
301-682-5507                                                                                                                                     
help@eBRap.org

 For more information, please contact Jill Sherman at intl.research@lakeheadu.ca.

External Deadline: 
Tuesday, November 29, 2022
Funding Source: 
External
Funding Level: 
Research